Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) EBT (2016 - 2025)

Veracyte (VCYT) has disclosed EBT for 14 consecutive years, with $40.6 million as the latest value for Q4 2025.

  • Quarterly EBT rose 1080.19% to $40.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $68.2 million through Dec 2025, up 164.92% year-over-year, with the annual reading at $68.2 million for FY2025, 164.92% up from the prior year.
  • EBT hit $40.6 million in Q4 2025 for Veracyte, up from $18.9 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $40.6 million in Q4 2025 to a low of -$45.7 million in Q1 2021.
  • Historically, EBT has averaged -$5.0 million across 5 years, with a median of -$8.2 million in 2023.
  • Biggest five-year swings in EBT: crashed 792.21% in 2023 and later surged 1080.19% in 2025.
  • Year by year, EBT stood at -$11.3 million in 2021, then skyrocketed by 69.7% to -$3.4 million in 2022, then plummeted by 792.21% to -$30.5 million in 2023, then soared by 111.3% to $3.4 million in 2024, then soared by 1080.19% to $40.6 million in 2025.
  • Business Quant data shows EBT for VCYT at $40.6 million in Q4 2025, $18.9 million in Q3 2025, and $1.2 million in Q2 2025.